Skip to main content
Erschienen in: Breast Cancer 4/2020

11.03.2020 | Original Article

Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction

verfasst von: Yayoi Adachi, Seiko Okumura, Masataka Sawaki, Masaya Hattori, Akiyo Yoshimura, Noami Gondo, Haruru Kotani, Madoka Iwase, Ayumi Kataoka, Kayoko Sugino, Nanae Horisawa, Yuri Ozaki, Yuka Endo, Shoko Sakamoto, Hiroji Iwata

Erschienen in: Breast Cancer | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Immediate breast reconstruction (IBR) has been become a standard treatment for patients with breast cancer undergoing mastectomy. However, whether IBR is appropriate in patients undergoing neoadjuvant chemotherapy (NAC) is still unclear. Therefore, in this study we examined the rates of operative adverse events (AEs), risk factors for operative AEs, and effects on chemotherapy and radiotherapy of IBR with NAC.

Methods

Between January 2012 and March 2018, 593 patients underwent IBR at the Aichi Cancer Center Hospital. We retrospectively obtained clinical data of all these patients from their medical records and identified 56 patients (65 breasts) who had received NAC (NAC group) and 537 patients (568 breasts) who had not (non-NAC group). We compared the rates of operative AEs, risk factors for operative AEs, chemotherapy-related AEs, and duration to radiotherapy between the NAC and non-NAC cohorts.

Results

The rate of operative AEs was significantly higher in the NAC than the non-NAC group (35% vs. 22%, p < 0.05). However, axillary lymph node dissection was the most influential risk factor, and NAC was not identified as a risk factor for operative AEs in patients who had undergone IBR. Additionally, there were no statistically significant differences in chemotherapy-related AEs or interval between surgery and postoperative radiotherapy between the NAC and non-NAC groups.

Conclusions

NAC remains likely to contribute to increased postoperative AEs in patients undergoing IBR; however, it does not affect postoperative treatment and IBR is appropriate for patients undergoing NAC.
Literatur
1.
Zurück zum Zitat Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;2:CD005002. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;2:CD005002.
2.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39.CrossRef Early Breast Cancer Trialists’ Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39.CrossRef
3.
Zurück zum Zitat Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.CrossRef Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.CrossRef
4.
Zurück zum Zitat Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189–200.CrossRef Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189–200.CrossRef
5.
Zurück zum Zitat Gouy S, Rouzier R, Missana MC, Atallah D, Youssef O, Barreau-Pouhaer L. Immediate reconstruction after neoadjuvant chemotherapy: effect on adjuvant treatment starting and survival. Ann Surg Oncol. 2005;12:161–6.CrossRef Gouy S, Rouzier R, Missana MC, Atallah D, Youssef O, Barreau-Pouhaer L. Immediate reconstruction after neoadjuvant chemotherapy: effect on adjuvant treatment starting and survival. Ann Surg Oncol. 2005;12:161–6.CrossRef
6.
Zurück zum Zitat Fernandez-Delgado J, Lopez-Pedraza MJ, Blasco JA, Andradas-Aragones E, Sanchez-Mendez JI, Sordo-Miralles G, et al. Satisfaction with and psychological impact of immediate and deferred breast reconstruction. Ann Oncol. 2008;19:1430–4.CrossRef Fernandez-Delgado J, Lopez-Pedraza MJ, Blasco JA, Andradas-Aragones E, Sanchez-Mendez JI, Sordo-Miralles G, et al. Satisfaction with and psychological impact of immediate and deferred breast reconstruction. Ann Oncol. 2008;19:1430–4.CrossRef
7.
Zurück zum Zitat Rowland JH, Desmond KA, Meyerowitz BE, Belin TR, Wyatt GE, Ganz PA. Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. J Natl Cancer Inst. 2000;92:1422–9.CrossRef Rowland JH, Desmond KA, Meyerowitz BE, Belin TR, Wyatt GE, Ganz PA. Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. J Natl Cancer Inst. 2000;92:1422–9.CrossRef
8.
Zurück zum Zitat Mitchem J, Herrmann D, Margenthaler JA, Aft RL. Impact of neoadjuvant chemotherapy on rate of tissue expander/implant loss and progression to successful breast reconstruction following mastectomy. Am J Surg. 2008;196:519–22.CrossRef Mitchem J, Herrmann D, Margenthaler JA, Aft RL. Impact of neoadjuvant chemotherapy on rate of tissue expander/implant loss and progression to successful breast reconstruction following mastectomy. Am J Surg. 2008;196:519–22.CrossRef
10.
Zurück zum Zitat Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.CrossRef Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.CrossRef
11.
Zurück zum Zitat Kataoka A, Sawaki M, Okumura S, Onishi S, Iwase M, Sugino K, et al. Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy. Breast J. 2019;25:202–6.CrossRef Kataoka A, Sawaki M, Okumura S, Onishi S, Iwase M, Sugino K, et al. Prediction of pathological margin status using preoperative contrast-enhanced MRI in patients with early breast cancer who underwent skin-sparing mastectomy. Breast J. 2019;25:202–6.CrossRef
12.
Zurück zum Zitat Di Monta G, Caraco C, Crispo A, Marone U, Mozzillo N. Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. World J Surg Oncol. 2012;10:275.CrossRef Di Monta G, Caraco C, Crispo A, Marone U, Mozzillo N. Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. World J Surg Oncol. 2012;10:275.CrossRef
13.
Zurück zum Zitat McCaul JA, Aslaam A, Spooner RJ, Louden I, Cavanagh T, Purushotham AD. Aetiology of seroma formation in patients undergoing surgery for breast cancer. Breast. 2000;9:144–8.CrossRef McCaul JA, Aslaam A, Spooner RJ, Louden I, Cavanagh T, Purushotham AD. Aetiology of seroma formation in patients undergoing surgery for breast cancer. Breast. 2000;9:144–8.CrossRef
14.
Zurück zum Zitat Deptula M, Zielinski J, Wardowska A, Pikula M. Wound healing complications in oncological patients: perspectives for cellular therapy. Postepy Dermatol Alergol. 2019;36:139–46.CrossRef Deptula M, Zielinski J, Wardowska A, Pikula M. Wound healing complications in oncological patients: perspectives for cellular therapy. Postepy Dermatol Alergol. 2019;36:139–46.CrossRef
15.
Zurück zum Zitat Abt NB, Flores JM, Baltodano PA, Sarhane KA, Abreu FM, Cooney CM, et al. Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. JAMA Surg. 2014;149:1068–76.CrossRef Abt NB, Flores JM, Baltodano PA, Sarhane KA, Abreu FM, Cooney CM, et al. Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction. JAMA Surg. 2014;149:1068–76.CrossRef
16.
Zurück zum Zitat Azzawi K, Ismail A, Earl H, Forouhi P, Malata CM. Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction. Plast Reconstr Surg. 2010;126:1–11.CrossRef Azzawi K, Ismail A, Earl H, Forouhi P, Malata CM. Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction. Plast Reconstr Surg. 2010;126:1–11.CrossRef
17.
Zurück zum Zitat Selber JC, Kurichi JE, Vega SJ, Sonnad SS, Serletti JM. Risk factors and complications in free TRAM flap breast reconstruction. Ann Plast Surg. 2006;56:492–7.CrossRef Selber JC, Kurichi JE, Vega SJ, Sonnad SS, Serletti JM. Risk factors and complications in free TRAM flap breast reconstruction. Ann Plast Surg. 2006;56:492–7.CrossRef
18.
Zurück zum Zitat Oh E, Chim H, Soltanian HT. The effects of neoadjuvant and adjuvant chemotherapy on the surgical outcomes of breast reconstruction. J Plast Reconstr Aesthet Surg. 2012;65:e267–e280280.CrossRef Oh E, Chim H, Soltanian HT. The effects of neoadjuvant and adjuvant chemotherapy on the surgical outcomes of breast reconstruction. J Plast Reconstr Aesthet Surg. 2012;65:e267–e280280.CrossRef
19.
Zurück zum Zitat Mehrara BJ, Santoro TD, Arcilla E, Watson JP, Shaw WW, Da Lio AL. Complications after microvascular breast reconstruction: experience with 1195 flaps. Plast Reconstr Surg. 2006;118:1100–9 (discussion 10-1).CrossRef Mehrara BJ, Santoro TD, Arcilla E, Watson JP, Shaw WW, Da Lio AL. Complications after microvascular breast reconstruction: experience with 1195 flaps. Plast Reconstr Surg. 2006;118:1100–9 (discussion 10-1).CrossRef
20.
Zurück zum Zitat Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668–85.CrossRef Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668–85.CrossRef
21.
Zurück zum Zitat Panhofer P, Ferenc V, Schutz M, Gleiss A, Dubsky P, Jakesz R, et al. Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo classification. Int J Surg. 2014;12:334–9.CrossRef Panhofer P, Ferenc V, Schutz M, Gleiss A, Dubsky P, Jakesz R, et al. Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo classification. Int J Surg. 2014;12:334–9.CrossRef
22.
Zurück zum Zitat Donker M, Hage JJ, Woerdeman LA, Rutgers EJ, Sonke GS, Vrancken Peeters MJ. Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer. Eur J Surg Oncol. 2012;38:25–30.CrossRef Donker M, Hage JJ, Woerdeman LA, Rutgers EJ, Sonke GS, Vrancken Peeters MJ. Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer. Eur J Surg Oncol. 2012;38:25–30.CrossRef
23.
Zurück zum Zitat Zweifel-Schlatter M, Darhouse N, Roblin P, Ross D, Zweifel M, Farhadi J. Immediate microvascular breast reconstruction after neoadjuvant chemotherapy: complication rates and effect on start of adjuvant treatment. Ann Surg Oncol. 2010;17:2945–50.CrossRef Zweifel-Schlatter M, Darhouse N, Roblin P, Ross D, Zweifel M, Farhadi J. Immediate microvascular breast reconstruction after neoadjuvant chemotherapy: complication rates and effect on start of adjuvant treatment. Ann Surg Oncol. 2010;17:2945–50.CrossRef
Metadaten
Titel
Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction
verfasst von
Yayoi Adachi
Seiko Okumura
Masataka Sawaki
Masaya Hattori
Akiyo Yoshimura
Noami Gondo
Haruru Kotani
Madoka Iwase
Ayumi Kataoka
Kayoko Sugino
Nanae Horisawa
Yuri Ozaki
Yuka Endo
Shoko Sakamoto
Hiroji Iwata
Publikationsdatum
11.03.2020
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 4/2020
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-020-01065-4

Weitere Artikel der Ausgabe 4/2020

Breast Cancer 4/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.